Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fas ligand in human serum

M Tanaka1, T Suda, K Haze

  • 1Osaka Bioscience Institute, Japan.

Nature Medicine
|March 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Significance of repeated resection for recurrent intrahepatic cholangiocarcinoma.

Hepato-gastroenterology·2009
Same author

Activational and organisational effects of gonadal steroids on sex-specific acetylcholine release in the dorsal hippocampus.

Journal of neuroendocrinology·2009
Same author

BCR-ABL promotes neutrophil differentiation in the chronic phase of chronic myeloid leukemia by downregulating c-Jun expression.

Leukemia·2009
Same author

Sex-specific 24-h acetylcholine release profile in the medial prefrontal cortex: simultaneous measurement of spontaneous locomotor activity in behaving rats.

Neuroscience·2009
Same author

FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer.

British journal of cancer·2008
Same author

Poor postoperative blood glucose control increases surgical site infections after surgery for hepato-biliary-pancreatic cancer: a prospective study in a high-volume institute in Japan.

The Journal of hospital infection·2008
Same journal

Generalizable AI predicts immunotherapy outcomes across cancers and treatments.

Nature medicine·2026
Same journal

Immune aging biomarkers for clinical trials.

Nature medicine·2026
Same journal

Lassa fever countermeasures gather pace.

Nature medicine·2026
Same journal

Why high scores do not mean application readiness for health AI.

Nature medicine·2026
Same journal

Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial.

Nature medicine·2026
Same journal

Biological aging might help to explain the rising risk of early-onset cancer.

Nature medicine·2026
See all related articles

Soluble Fas ligand (sFasL) is elevated in patients with LGL leukemia and NK cell lymphoma, causing tissue damage. Neutralizing Fas ligand (FasL) or inhibiting its conversion may treat these conditions.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Fas ligand (FasL) induces apoptosis in target cells.
  • FasL can be converted from a membrane-bound to a soluble form (sFasL).

Purpose of the Study:

  • To investigate the role of sFasL in large granular lymphocytic (LGL) leukemia and natural killer (NK) cell lymphoma.
  • To develop methods for detecting and neutralizing sFasL.

Main Methods:

  • Developed two neutralizing monoclonal anti-human FasL antibodies.
  • Established an enzyme-linked immunosorbent assay (ELISA) for sFasL detection in human sera.
  • Analyzed FasL expression on malignant cells and healthy NK cells.

Main Results:

  • Healthy sera showed no detectable sFasL; LGL leukemia and NK cell lymphoma sera were positive.

Related Experiment Videos

  • Malignant cells constitutively expressed FasL, while healthy NK cells expressed it upon activation.
  • sFasL is produced by malignant cells in these conditions.

    • Conclusions:

    • Elevated sFasL in LGL leukemia and NK cell lymphoma contributes to systemic tissue damage.
    • Neutralizing anti-FasL antibodies or matrix metalloproteinase inhibitors are potential therapeutic strategies.